Literature DB >> 23990689

A Patient Focused Solution for Enrolling Clinical Trials in Rare and Selective Cancer Indications: A Landscape of Haystacks and Needles.

Eric B Lynam1, Jiin Leaw, Matthew B Wiener.   

Abstract

Participation of adult cancer patients in US based clinical trials has remained near 3% for decades. Traditional research methodology reaches a small fraction of the target population with a fixed number of predetermined sites. Solutions are needed to ethically increase patient participation and accelerate cancer trial completion. We compared enrollment outcomes of traditional and patient focused research methodologies. A patient prioritized method (Just-In-Time, JIT) was implemented in parallel with traditionally managed sites in three cancer trials. JIT research sites were initiated after candidate patients presented, while traditional sites were initiated in advance. JIT sites enrolled with mean rates no less than, and up to 2.75 fold greater than, traditional sites. Mean patients enrolled per site was comparable (JIT-1.82, traditional-1.78). There were fewer non-enrolling JIT sites (2/28, 7%) compared to traditional sites 19/52, 37%). This retrospective analysis supports JIT as a prospective solution to increase cancer clinical trial enrollment and the efficiency of clinical trial administrative activities.

Entities:  

Year:  2012        PMID: 23990689      PMCID: PMC3754447          DOI: 10.1177/0092861512443436

Source DB:  PubMed          Journal:  Drug Inf J        ISSN: 0092-8615


  15 in total

1.  Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B.

Authors:  David M Dilts; Alan B Sandler; Matthew Baker; Steven K Cheng; Stephen L George; Kathleen S Karas; Stephen McGuire; Gourija S Menon; Jason Reusch; Debbie Sawyer; Maren Scoggins; Amy Wu; Kai Zhou; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

2.  Cancer: the road to Amiens.

Authors:  David J Stewart; Razelle Kurzrock
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

3.  Factors influencing enrollment in clinical trials for cancer treatment.

Authors:  C N Klabunde; B C Springer; B Butler; M S White; J Atkins
Journal:  South Med J       Date:  1999-12       Impact factor: 0.954

Review 4.  Barriers to clinical trials. Part I: Reimbursement problems.

Authors:  I D Fleming
Journal:  Cancer       Date:  1994-11-01       Impact factor: 6.860

5.  A population-based assessment of specialty physician involvement in cancer clinical trials.

Authors:  Carrie N Klabunde; Nancy L Keating; Arnold L Potosky; Anita Ambs; Yulei He; Mark C Hornbrook; Patricia A Ganz
Journal:  J Natl Cancer Inst       Date:  2011-02-11       Impact factor: 13.506

6.  Clinical trial accrual among new cancer patients at a community-based cancer center.

Authors:  Ronald S Go; Kathleen A Frisby; Jennifer A Lee; Michelle A Mathiason; Christine M Meyer; Jodi L Ostern; Sara M Walther; Jonean E Schroeder; Lori A Meyer; Kathryn E Umberger
Journal:  Cancer       Date:  2006-01-15       Impact factor: 6.860

7.  Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials.

Authors:  David M Dilts; Alan B Sandler
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

8.  A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies.

Authors:  Steven K Cheng; Mary S Dietrich; David M Dilts
Journal:  Clin Cancer Res       Date:  2010-11-09       Impact factor: 12.531

9.  Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials.

Authors:  H A Tejeda; S B Green; E L Trimble; L Ford; J L High; R S Ungerleider; M A Friedman; O W Brawley
Journal:  J Natl Cancer Inst       Date:  1996-06-19       Impact factor: 13.506

10.  Commentary: tackling the challenges of developing targeted therapies for cancer.

Authors:  Richard L Schilsky; Jeff Allen; Joshua Benner; Ellen Sigal; Mark McClellan
Journal:  Oncologist       Date:  2010
View more
  4 in total

Review 1.  Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology.

Authors:  Jessica J Tao; Alison M Schram; David M Hyman
Journal:  Annu Rev Med       Date:  2017-11-09       Impact factor: 13.739

2.  Comparison of Web-Based Advertising and a Social Media Platform as Recruitment Tools for Underserved and Hard-to-Reach Populations in Rheumatology Clinical Research.

Authors:  Vladislav Tsaltskan; Katherine Nguyen; Christina Eaglin; V Michael Holers; Kevin D Deane; Gary S Firestein
Journal:  ACR Open Rheumatol       Date:  2022-05-10

Review 3.  Ethical considerations of neuro-oncology trial design in the era of precision medicine.

Authors:  Saksham Gupta; Timothy R Smith; Marike L Broekman
Journal:  J Neurooncol       Date:  2017-05-29       Impact factor: 4.130

4.  Signature program: a platform of basket trials.

Authors:  Eric D Slosberg; Barinder P Kang; Julio Peguero; Matthew Taylor; Todd M Bauer; Donald A Berry; Fadi Braiteh; Alexander Spira; Funda Meric-Bernstam; Steven Stein; Sarina A Piha-Paul; August Salvado
Journal:  Oncotarget       Date:  2018-04-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.